Evidence map›Paper›PMID 19420078›Full record

ArticleJournal of virology2009

Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.

Makoto Kubo, Yoshiaki Nishimura, Masashi Shingai, Wendy Lee, Jason Brenchley, Bernard Lafont, Alicia Buckler-White, Tatsuhiko Igarashi, Malcolm A Martin

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Antiretroviral-based HIV prevention strategies for women.Expert review of anti-infective therapy · 2010
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Makoto KuboLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 2089-0460, USA.
Yoshiaki Nishimura
Masashi Shingai
Wendy Lee
Jason Brenchley
Bernard Lafont
Alicia Buckler-White
Tatsuhiko Igarashi
Malcolm A Martin
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Mechanisms of Immune Activation and Disease Progression in Animal ModelsZIAAI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2009 to 2025
$28.2M
Primate Lentivirus PathogenesisZIAAI000998 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2009 to 2015
$11.3M
Primate Lentivirus PathogenesisZ01AI000998 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI MARTIN, MALCOLM · 2007 to 2008
$4.6M
AIDS Animal Models: Cellular Immunology and ImmunogeneticsZIAAI001026 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LAFONT, BERNARD · 2009 to 2012
$2.4M
Mechanisms of Immune Activation and Disease Progression in Animal ModelsZ01AI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2008 to 2008
$455k
AIDS Animal Models: Cellular Immunology and ImmunogeneticsZ01AI001026 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LAFONT, BERNARD · 2008 to 2008
$397k
6 · The paper itself

Abstract

We investigated whether a 28-day course of potent antiretroviral therapy, initiated at a time point (48 h postinoculation) following simian immunodeficiency virus (SIV) inoculation when the acquisition of a viral infection was virtually assured, would sufficiently sensitize the immune system and result in controlled virus replication when treatment was stopped. The administration of tenofovir 48 h after SIV inoculation to six Mamu-A*01-negative rhesus macaques did, in fact, potently suppress virus replication in all of the treated rhesus macaques, but plasma viral RNA rapidly became detectable in all six animals following its cessation. Unexpectedly, the viral set points in the treated monkeys became established at two distinct levels. Three controller macaques had chronic phase virus loads in the range of 1 x 10(3) RNA copies/ml, whereas three noncontroller animals had set points of 2 x 10(5) to 8 x 10(5) RNA copies/ml. All of the noncontroller monkeys died with symptoms of immunodeficiency by week 60 postinfection, whereas two of the three controller animals were alive at week 80. Interestingly, the three controller macaques each carried major histocompatibility complex class I alleles that previously were reported to confer protection against SIV, and two of these animals generated cytotoxic T-lymphocyte escape viral variants during the course of their infections.

Indexed as

AdenineAmino Acid SequenceAnimalsAnti-HIV AgentsCD4-Positive T-LymphocytesCells, CulturedDisease Models, AnimalDrug Administration ScheduleHIV AntibodiesHIV InfectionsHumansInjectionsMacaca mulattaMolecular Sequence DataOrganophosphonatesSequence AlignmentAdenineAnti-HIV AgentsHIV AntibodiesOrganophosphonatesTenofovir

Identifiers

PMID19420078
PMCPMC2704794
OpenAlexW2157182826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.